![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCDC141 |
Gene summary for CCDC141 |
![]() |
Gene information | Species | Human | Gene symbol | CCDC141 | Gene ID | 285025 |
Gene name | coiled-coil domain containing 141 | |
Gene Alias | CAMDI | |
Cytomap | 2q31.2 | |
Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | B8ZZB3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
285025 | CCDC141 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 7.31e-03 | 5.54e-01 | -0.1406 |
285025 | CCDC141 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.67e-11 | 6.10e-01 | -0.2116 |
285025 | CCDC141 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.37e-02 | 4.54e-01 | -0.1941 |
285025 | CCDC141 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 7.22e-04 | 5.15e-01 | -0.2107 |
285025 | CCDC141 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.58e-07 | 4.38e-01 | -0.2119 |
285025 | CCDC141 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.39e-03 | 2.15e-01 | -0.0166 |
285025 | CCDC141 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 4.32e-03 | 1.56e-01 | -0.013 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00219872 | Lung | IAC | cerebral cortex development | 27/2061 | 114/18723 | 8.78e-05 | 1.77e-03 | 27 |
GO:00215432 | Lung | IAC | pallium development | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
GO:00309002 | Lung | IAC | forebrain development | 61/2061 | 379/18723 | 1.52e-03 | 1.61e-02 | 61 |
GO:00516424 | Lung | IAC | centrosome localization | 10/2061 | 32/18723 | 1.68e-03 | 1.76e-02 | 10 |
GO:00618424 | Lung | IAC | microtubule organizing center localization | 10/2061 | 33/18723 | 2.18e-03 | 2.15e-02 | 10 |
GO:0021795 | Lung | IAC | cerebral cortex cell migration | 11/2061 | 42/18723 | 4.72e-03 | 3.68e-02 | 11 |
GO:0022029 | Lung | IAC | telencephalon cell migration | 13/2061 | 56/18723 | 6.78e-03 | 4.73e-02 | 13 |
GO:003090011 | Lung | AIS | forebrain development | 55/1849 | 379/18723 | 2.37e-03 | 2.48e-02 | 55 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC141 | SNV | Missense_Mutation | novel | c.1238N>A | p.Ser413Tyr | p.S413Y | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCDC141 | SNV | Missense_Mutation | novel | c.1814N>G | p.Val605Gly | p.V605G | protein_coding | tolerated(0.41) | benign(0.001) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC141 | SNV | Missense_Mutation | c.1950N>T | p.Lys650Asn | p.K650N | protein_coding | deleterious_low_confidence(0) | benign(0.143) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CCDC141 | SNV | Missense_Mutation | rs376518328 | c.1086G>T | p.Lys362Asn | p.K362N | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCDC141 | SNV | Missense_Mutation | novel | c.1758N>T | p.Lys586Asn | p.K586N | protein_coding | tolerated(0.07) | benign(0.114) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC141 | SNV | Missense_Mutation | c.1244N>A | p.Ser415Tyr | p.S415Y | protein_coding | tolerated(0.29) | benign(0.069) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | ||
CCDC141 | SNV | Missense_Mutation | novel | c.1280N>A | p.Gly427Asp | p.G427D | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
CCDC141 | SNV | Missense_Mutation | novel | c.1776G>T | p.Lys592Asn | p.K592N | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
CCDC141 | SNV | Missense_Mutation | rs372879210 | c.1003N>T | p.Arg335Trp | p.R335W | protein_coding | deleterious(0) | possibly_damaging(0.742) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC141 | SNV | Missense_Mutation | c.2549N>G | p.Asp850Gly | p.D850G | protein_coding | tolerated(1) | benign(0) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |